The validation of JASPAC 01 clinical trial and the analyses of the multi-omics data to promote individualized adjuvant chemotherapy in pancreatic cancer patients

2015 Fiscal Year Final Research Report

• Project/Area Number: 26870919
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Medical genome science; Digestive surgery
• Research Institution: Shizuoka Cancer Center Research Institute
• Principal Investigator: Okamura Yukiyasu 静岡県立静岡がんセンター(研究所), その他部局等, 医長 (10704489)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: 膵癌 / 膵臓外科学 / ゲノム医科学 / 個別化治療

Outline of Final Research Achievements

Whole exon sequencing (WES, Life Technologies) and gene expression profiling (GEP, Agilent Technologies) were performed for 22 patients who underwent pancreatectomy for pancreatic cancer. The impaired expression of KRAS, TP53 and p16 genes of 4 mafor genes which were frequently mutated in pancreatic cancer was detected in fifteen, twelve and four cases, respectively. In the tumor tissue, many cases increased expression of tyrosine kinase receptors. The hyper-expression of FGFR3 and ERBB3 was identified in six cases each. Moreover, JAK3 and CSFIR were identified in two cases each. The recurrence-free and overall survival rate among the patients with the increased expression of FGFR3 were significantly poorer than those without the increased expression of FGFR3 (P=0.047 and P=0.048, respectively).

Free Research Field

消化器外科学